Treatment of Kratom Withdrawal Without Buprenorphine/Suboxone
When buprenorphine is unavailable or inappropriate for kratom withdrawal, use α2-adrenergic agonists (clonidine or lofexidine) as first-line symptomatic treatment, combined with targeted medications for specific withdrawal symptoms.
Primary Pharmacological Approach
α2-Adrenergic Agonists (First-Line)
Clonidine or lofexidine directly attenuate opioid-like withdrawal symptoms that occur with kratom cessation 1, 2. These agents work by suppressing the hyperadrenergic state characteristic of opioid withdrawal. Research confirms their effectiveness in kratom withdrawal specifically 3, 4.
- Clonidine: Start with small initial doses and titrate carefully due to risk of orthostasis and hypotension 1
- Lofexidine: FDA-approved for opioid withdrawal control; less likely to cause hypotension than clonidine 1, 2
- Clinical evidence: A case report demonstrated successful kratom detoxification using lofexidine combined with dihydrocodeine 4
Important caveat: Monitor blood pressure closely, especially in patients who may be volume depleted or have cardiovascular comorbidities.
Symptom-Targeted Medications
The withdrawal syndrome from kratom mirrors opioid withdrawal with both psychological and physical components 5. Address specific symptoms with the following agents 1, 2:
For anxiety, insomnia, and irritability:
- Trazodone
- Gabapentin
- Mirtazapine
- Benzodiazepines (short-term use only; help reduce catecholamine release and alleviate muscle cramps)
For gastrointestinal symptoms:
- Loperamide for diarrhea (use cautiously—can be abused and causes dangerous arrhythmias in high doses) 1
- Antiemetics (promethazine or ondansetron) for nausea/vomiting 2
For myalgias and body aches:
- NSAIDs or acetaminophen
- Benzodiazepines for muscle cramps
Alternative Opioid Replacement (When Appropriate)
Methadone
Methadone can be effective for kratom withdrawal but requires specialized settings 6. A recent 2025 study showed 93% treatment retention in 14 patients with kratom use disorder treated with methadone in Opioid Treatment Programs 6.
- Mean effective dose: 98.6 mg (range 35-190 mg)
- Mean starting dose: 27.5 mg (range 15-30 mg)
- Critical restriction: Can only be dispensed for opioid use disorder through licensed Opioid Treatment Programs 2
- Emergency exception: Single doses may be administered in ED for up to 72 hours while arranging referral 2
Major caution: Avoid converting outpatients to methadone for weaning due to complex pharmacokinetics, nonlinear morphine equivalency, multiple drug interactions, and high lethality risk 1. This is especially true for patients on high kratom doses.
Clinical Withdrawal Timeline and Monitoring
Kratom withdrawal symptoms include 5:
- Psychological: Depressed mood, anxiety, restlessness, irritability, tension, loss of concentration
- Physical: Myalgia, joint pain, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, feverish sensation, loss of appetite, tremors, pruritus, chills
Withdrawal typically lasts at least 5 days based on animal models 3, though human case reports suggest variable duration. The withdrawal is generally shorter and more benign than full opioid agonist withdrawal 4.
Treatment Algorithm
Assess withdrawal severity using Clinical Opiate Withdrawal Scale (COWS) if available 7
Initiate α2-agonist therapy:
- Start clonidine or lofexidine at low doses
- Monitor blood pressure before each dose
- Titrate based on symptom control
Add symptom-specific medications:
- Trazodone or mirtazapine for insomnia (evening dosing)
- Gabapentin for anxiety and restlessness (can dose TID)
- Loperamide for diarrhea (standard doses only)
- Antiemetics as needed
Consider short-term benzodiazepines for severe anxiety or muscle cramps (3-7 days maximum)
Provide supportive care:
- Hydration
- Nutritional support
- Reassurance about time-limited nature of symptoms
Special Considerations
Drug interactions: Kratom inhibits cytochrome P450 enzymes and P-glycoprotein 8, which may affect metabolism of other medications. Review all concurrent medications when managing withdrawal.
Pregnancy: Three case reports describe successful buprenorphine use for kratom withdrawal in pregnancy 9, but when buprenorphine is unavailable, symptomatic management with careful medication selection is necessary. Avoid medications with teratogenic potential.
Neonatal withdrawal: Infants born to mothers using kratom may experience withdrawal symptoms including oral intolerance, restlessness, irritability, and vomiting 5.
Evidence Quality Note
The evidence base for kratom withdrawal treatment is limited compared to traditional opioid withdrawal. Most data comes from case reports and small case series 5, 4, 9, 6, 7, 8. However, the pharmacological rationale is sound given kratom's partial mu-opioid agonist activity through mitragynine and 7-hydroxymitragynine 5. The symptomatic treatment approach mirrors established opioid withdrawal management protocols from major guidelines 1, 2.